Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 3-4/2020

01.02.2020 | editorial

Interventional treatment of tricuspid regurgitation

An important innovation in cardiology

verfasst von: MD, PhD Georg Goliasch, MD Julia Mascherbauer

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 3-4/2020

Einloggen, um Zugang zu erhalten
share
TEILEN

Excerpt

Significant tricuspid regurgitation (TR) is a common condition affecting more than 2% of individuals over the age of 75 years [ 1]. In the overwhelming majority of cases tricuspid regurgitation develops secondarily. It is the result of incomplete leaflet coaptation caused by tricuspid annular dilatation and/or leaflet tethering due to right ventricular dilatation. Progressive volume overload of the right ventricle promotes a vicious circle characterized by further dilatation of right ventricle, tricuspid annulus and right atrium, which promotes further worsening of TR. Frequently, patients presenting with significant TR also suffer from atrial fibrillation, which may contribute to further annular dilatation. Long-standing TR, specifically in the setting of increased pulmonary pressures, can promote irreversible structural right ventricular, tricuspid annular and right atrial remodelling. It is associated with impaired prognosis in heart failure with preserved as well as reduced ejection fraction [ 2, 3]. An increasing body of evidence also relates moderate/severe TR to an increased mortality risk, which is independent of pulmonary pressures or right ventricular (RV) function [ 4, 5]. …
Literatur
2.
Zurück zum Zitat Mascherbauer J, Kammerlander AA, Zotter-Tufaro C, Aschauer S, Duca F, Dalos D, et al. Presence of isolated tricuspid regurgitation should prompt the suspicion of heart failure with preserved ejection fraction. PLoS ONE. 2017;12(2):e171542. CrossRef Mascherbauer J, Kammerlander AA, Zotter-Tufaro C, Aschauer S, Duca F, Dalos D, et al. Presence of isolated tricuspid regurgitation should prompt the suspicion of heart failure with preserved ejection fraction. PLoS ONE. 2017;12(2):e171542. CrossRef
3.
Zurück zum Zitat Neuhold S, Huelsmann M, Pernicka E, Graf A, et al. Impact of tricuspid regurgitation on survival in patients with chronic heart failure: unexpected findings of a long-term observational study. Eur Heart J. 2013;34(11):844–52. CrossRef Neuhold S, Huelsmann M, Pernicka E, Graf A, et al. Impact of tricuspid regurgitation on survival in patients with chronic heart failure: unexpected findings of a long-term observational study. Eur Heart J. 2013;34(11):844–52. CrossRef
4.
Zurück zum Zitat Wang N, Fulcher J, Abeysuriya N, et al. Tricuspid regurgitation is associated with increased mortality independent of pulmonary pressures and right heart failure: a systematic review and meta-analysis. Eur Heart J. 2019;40(5):476–84. CrossRef Wang N, Fulcher J, Abeysuriya N, et al. Tricuspid regurgitation is associated with increased mortality independent of pulmonary pressures and right heart failure: a systematic review and meta-analysis. Eur Heart J. 2019;40(5):476–84. CrossRef
5.
Zurück zum Zitat Bartko PE, Arfsten H, Frey MK, et al. Natural history of functional tricuspid regurgitation: implications of quantitative doppler assessment. JACC Cardiovasc Imaging. 2019;12(3):389–97. CrossRef Bartko PE, Arfsten H, Frey MK, et al. Natural history of functional tricuspid regurgitation: implications of quantitative doppler assessment. JACC Cardiovasc Imaging. 2019;12(3):389–97. CrossRef
6.
Zurück zum Zitat Kim YJ, Kwon DA, Kim HK, et al. Determinants of surgical outcome in patients with isolated tricuspid regurgitation. Circulation. 2009;120(17):1672–8. CrossRef Kim YJ, Kwon DA, Kim HK, et al. Determinants of surgical outcome in patients with isolated tricuspid regurgitation. Circulation. 2009;120(17):1672–8. CrossRef
7.
Zurück zum Zitat Topilsky Y, Khanna AD, Oh JK, et al. Preoperative factors associated with adverse outcome after tricuspid valve replacement. Circulation. 2011;123(18):1929–39. CrossRef Topilsky Y, Khanna AD, Oh JK, et al. Preoperative factors associated with adverse outcome after tricuspid valve replacement. Circulation. 2011;123(18):1929–39. CrossRef
8.
Zurück zum Zitat Axtell AL, Bhambhani V, Moonsamy P, et al. Surgery does not improve survival in patients with isolated severe tricuspid regurgitation. J Am Coll Cardiol. 2019;74(6):715–25. CrossRef Axtell AL, Bhambhani V, Moonsamy P, et al. Surgery does not improve survival in patients with isolated severe tricuspid regurgitation. J Am Coll Cardiol. 2019;74(6):715–25. CrossRef
9.
Zurück zum Zitat Overtchouk P, Piazza N, Granada J, Soliman O, Prendergast B, Modine T. Advances in transcatheter mitral and tricuspid therapies. BMC Cardiovasc Disord. 2020;20(1):1. CrossRef Overtchouk P, Piazza N, Granada J, Soliman O, Prendergast B, Modine T. Advances in transcatheter mitral and tricuspid therapies. BMC Cardiovasc Disord. 2020;20(1):1. CrossRef
10.
Zurück zum Zitat Nickenig G, Weber M, Lurz P, et al. Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6‑month outcomes of the TRILUMINATE single-arm study. Lancet. 2019;394(10213):2002–11. CrossRef Nickenig G, Weber M, Lurz P, et al. Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6‑month outcomes of the TRILUMINATE single-arm study. Lancet. 2019;394(10213):2002–11. CrossRef
11.
Zurück zum Zitat Hasenfuss G, Hayward C, Burkhoff D, et al. A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial. Lancet. 2016;387(10025):1298–304. CrossRef Hasenfuss G, Hayward C, Burkhoff D, et al. A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial. Lancet. 2016;387(10025):1298–304. CrossRef
12.
Zurück zum Zitat Sanon S, Cabalka AK, Babaliaros V, Rihal C, Gafoor S, Webb J, et al. Transcatheter tricuspid valve-in-valve and valve-in-ring implantation for degenerated surgical prosthesis. JACC Cardiovasc Interv. 2019;12(15):1403–12. CrossRef Sanon S, Cabalka AK, Babaliaros V, Rihal C, Gafoor S, Webb J, et al. Transcatheter tricuspid valve-in-valve and valve-in-ring implantation for degenerated surgical prosthesis. JACC Cardiovasc Interv. 2019;12(15):1403–12. CrossRef
13.
Zurück zum Zitat Figulla HR, Kiss K, Lauten A. Transcatheter interventions for tricuspid regurgitation—heterotopic technology: TricValve. EuroIntervention. 2016;12(Y):Y116–Y8. CrossRef Figulla HR, Kiss K, Lauten A. Transcatheter interventions for tricuspid regurgitation—heterotopic technology: TricValve. EuroIntervention. 2016;12(Y):Y116–Y8. CrossRef
14.
Zurück zum Zitat Asmarats L, Puri R, Latib A, Navia JJL, Rodés-Cabau J. Transcatheter tricuspid valve interventions: landscape, challenges, and future directions. J Am Coll Cardiol. 2018;71(25):2935–56. CrossRef Asmarats L, Puri R, Latib A, Navia JJL, Rodés-Cabau J. Transcatheter tricuspid valve interventions: landscape, challenges, and future directions. J Am Coll Cardiol. 2018;71(25):2935–56. CrossRef
Metadaten
Titel
Interventional treatment of tricuspid regurgitation
An important innovation in cardiology
verfasst von
MD, PhD Georg Goliasch
MD Julia Mascherbauer
Publikationsdatum
01.02.2020
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 3-4/2020
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-020-01621-0